Olatokunbo Osibogun

Dr. Olatokunbo Osibogun

Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Trends in Cardiovascular Medicine
Verified
Journal Article
Open access
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
OOOluseye Ogunmoroti
Oluseye Ogunmoroti
EMErin D. Michos
Erin D. Michos
Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.

1 January 2022 in Preventive Medicine
Verified
Journal Article
Closed access
OOOluseye Ogunmoroti
Oluseye Ogunmoroti
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
ESErica S. Spatz
Erica S. Spatz
VOVictor Okunrintemi
Victor Okunrintemi
LMLena Mathews
Lena Mathews
EMErin D. Michos
Erin D. Michos

1 June 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
ZTZiyad Ben Taleb
Ziyad Ben Taleb
RBRaed Bahelah
Raed Bahelah
RSRamzi G. Salloum
Ramzi G. Salloum
WMWasim Maziak
Wasim Maziak

5 July 2019 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
OOOluseye Ogunmoroti
Oluseye Ogunmoroti
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
OKOlamide B. Kolade
Olamide B. Kolade
WYWendy Ying
Wendy Ying
GSGarima Sharma
Garima Sharma
EMErin D. Michos
Erin D. Michos

1 May 2020 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
ZBZoran Bursac
Zoran Bursac
WMWasim Maziak
Wasim Maziak

23 June 2017 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
Olatokunbo OsibogunOlatokunbo Osibogun
Olatokunbo Osibogun
OOOluseye Ogunmoroti
Oluseye Ogunmoroti
EME. D. Michos
E. D. Michos
ESE. S. Spatz
E. S. Spatz
BOB. Olubajo
B. Olubajo
WMW. Maziak
W. Maziak